|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen.
|
31800347 |
2020 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.
|
31559573 |
2020 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genotyping of clinically relevant <i>CYP2D6</i> alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy.
|
31178724 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
|
31195002 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
|
29135105 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results are consistent with the relatively few other large, population-based studies conducted to date that have not observed an increased risk of adverse BC outcomes associated with CYP2D6 inhibition.
|
30542984 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
|
30843495 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.
|
30357449 |
2019 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the interaction of CYP2C19 and CYP2D6 genotype on clinical outcome in tamoxifen-treated breast cancer patients.
|
30022682 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer.
|
29385237 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
|
29396856 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From our review of published data we found that standardization of CYP2D6 genotype-phenotype classification is needed in order to ensure effective evaluation of associations between CYP2D6 polymorphisms and endoxifen concentrations and BC outcomes.
|
28762370 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients.
|
29473149 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
|
28730340 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer.
|
28798474 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
|
28592184 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
|
28955222 |
2017 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Summary estimates of association, with or without bias adjustment, indicated no clinically important association between CYP2D6 genotype and breast cancer survival in tamoxifen-treated women.
|
27988492 |
2017 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
|
28745555 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In response to: Damkier P. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.Pharmacogenomics 18(8), XXX (2017).
|
28593824 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In relation to CYP2D6 genotype, CYP2D6*10/*10 is more frequently observed in both Malaysian Malay (28.9%) and Chinese (57.1%) breast cancer patients, whereas CYP2D6*4/*10 is more frequently observed in Malaysian Indian (42.8%) breast cancer patients.
|
26510986 |
2016 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
|
27484880 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Trials examining tamoxifen dose escalation and breast cancer outcome should be guided by endoxifen levels alone, without reference to CYP2D6 genotype or presence of hot flashes.Clin Cancer Res; 22(13); 3164-71.
|
26847054 |
2016 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blood samples from 279 Polish women with breast cancer receiving tamoxifen 20 mg daily were analyzed for CYP2D6 genotype and drug metabolite concentration.
|
26232141 |
2015 |